TuHURA Biosciences, Inc. | WebDisclosure

Basculer en Français

8295	Companies
114850	Keywords
55292	Articles
62440	Press releases

Headlines Articles Press releases TuHURA Biosciences, Inc.

Home
Companies
TuHURA Biosciences, Inc.

BRIEF

published on 08/19/2024 at 15:05, 3 months 1 day ago

Kineta Inc. rouvre les inscriptions pour l'essai clinique VISTA-101

TuHURA Biosciences Essai Clinique Oncologie KVA12123 Kineta Inc.
PRESS RELEASE

published on 08/19/2024 at 15:00, 3 months 1 day ago

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
Kineta reopens enrollment for VISTA-101 clinical trial with KVA12123 antibody. Positive results at AACR 2024. TuHURA and Kineta join forces. Acquisition pending. Kintara merger progresses

Merger TuHURA Kineta KVA12123 VISTA-101
BRIEF

published on 07/08/2024 at 12:35, 4 months 12 days ago

TuHURA Biosciences Secures Exclusive Rights for Kineta’s KVA12123 Checkpoint Inhibitor

TuHURA Keytruda Kineta Checkpoint Inhibitor VISTA
BRIEF

published on 07/08/2024 at 12:35, 4 months 12 days ago

TuHURA Biosciences obtient les droits exclusifs pour l'inhibiteur de point de contrôle KVA12123 de Kineta

TuHURA Vue Kineta Inhibiteur De Point De Contrôle CLÉTRUDA
PRESS RELEASE

published on 07/08/2024 at 12:30, 4 months 12 days ago

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
TuHURA Biosciences and Kintara Therapeutics announce an Exclusivity Agreement for potential acquisition of KVA12123 anti-VISTA antibody. KVA12123 aims to reverse VISTA immune suppression and enhance tumor immunity

TuHURA Biosciences Immunotherapy Kintara Therapeutics KVA12123 VISTA Antibody
BRIEF

published on 07/01/2024 at 14:40, 4 months 19 days ago

Kintara Therapeutics et TuHURA Biosciences annoncent des mises à jour corporatives et cliniques

Biopharmaceutique TuHURA Biosciences Essais Cliniques Fusionnement Kintara Thérapeutique
BRIEF

published on 07/01/2024 at 14:40, 4 months 19 days ago

Kintara Therapeutics and TuHURA Biosciences Announce Corporate and Clinical Updates

Merger Clinical Trials Biopharmaceutical TuHURA Biosciences Kintara Therapeutics
PRESS RELEASE

published on 07/01/2024 at 14:35, 4 months 19 days ago

Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
Kintara Therapeutics, Inc. and TuHURA Biosciences, Inc. provide overview of recent corporate and clinical advancements, with upcoming milestones including merger closing and clinical trial commencement

Merger Agreement TuHURA Biosciences Phase 3 Trial Kintara Therapeutics Clinical Advancements
BRIEF

published on 06/03/2024 at 14:40, 5 months 17 days ago

TuHURA Biosciences et Kintara Therapeutics rapportent des résultats positifs de l'essai de phase 1b de l'IFx-2.0

IFx-2.0 Vaccin Personnalisé Contre Le Cancer Résultats Des Essais Cliniques Carcinome À Cellules De Merkel Inhibiteurs De Points De Contrôle Immunitaires
BRIEF

published on 06/03/2024 at 14:40, 5 months 17 days ago

TuHURA Biosciences and Kintara Therapeutics Report Positive Results from Phase 1b Trial of IFx-2.0

IFx-2.0 Clinical Trial Results Personalized Cancer Vaccine Merkel Cell Carcinoma Immune Checkpoint Inhibitors

Accesswire

Published on 11/21/2024 at 11:30, 22 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 1 hour 49 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 1 hour 52 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 2 hours 52 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 11 hours 17 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 11:30, 21 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 50 minutes ago

Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 11:00, 51 minutes ago

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
Published on 11/21/2024 at 10:56, 55 minutes ago

ABO Energy closes sale for two Battery Projects in South Africa
Published on 11/21/2024 at 10:30, 1 hour 21 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024

Les Echos

Published on 11/21/2024 at 06:58, 4 hours 54 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 54 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 54 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 15 hours 44 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 16 hours 31 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE